Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868029 | 1.00 | OPRL1 (0.45) | OPRL1CYP2D6CCR1IRAK4KDM1A | |
| SCHEMBL2873636 | 0.82 | MEN1 (0.43) | OPRL1CYP2D6CCR1RORC | |
| SCHEMBL2873632 | 0.82 | MEN1 (0.43) | OPRL1CYP2D6CCR1RORC | |
| SCHEMBL16789699 | 0.82 | CCR1 (0.47) | CYP2D6CCR1OPRM1 | |
| SCHEMBL15180475 | 0.81 | IRAK4 (0.40) | OPRL1IRAK4 | |
| SCHEMBL15185418 | 0.81 | IRAK4 (0.40) | OPRL1IRAK4 | |
| SCHEMBL521027 | 0.81 | PDE4B (0.42) | OPRL1IRAK4 | |
| SCHEMBL521028 | 0.81 | PDE4B (0.42) | OPRL1IRAK4 | |
| Hydrochloric Acid SCHEMBL16763575 | 0.81 | CCR1 (0.46) | CYP2D6CCR1OPRM1 | |
| SCHEMBL3903587 | 0.79 | OPRM1 (0.40) | OPRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1811998-B1 | TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7645775-B2 | Triazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070270410-A1 | Triazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| EP-1811998-A1 | TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006047256-A1 | TRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270410-A1 | Triazoles useful as inhibitors of protein kinases | MAP3K20, MAP3K3, MAP3K1 | OPRL1 4357/4885CYP2D6 3741/4885CCR1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.